Abstracts tagged "biomarkers and rheumatoid arthritis (RA)"

Abstract Number: 564 • 2018 ACR/ARHP Annual Meeting
Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)
Katie Tuckwell¹, Cem Gabay², Thierry Sornasse¹, Ruediger Laubender³, Jianmei Wang⁴ and Michael Townsend¹, ¹Genentech, Inc., South San Francisco, CA, ²University Hospitals of Geneva, Geneva, Switzerland, ³Roche Diagnostics, Penzberg, Germany, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: The biomarkers CXCL13 and sICAM1 have been associated with outcomes in patients with RA treated with TCZ. This study evaluated the association of CXCL13…
Abstract Number: 1474 • 2018 ACR/ARHP Annual Meeting
Circulating Transfer RNA-Derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Qiong Wu, Quanhu Sheng, Joseph F. Solus, Kasey Vickers, Ryan Allen, Shilin Zhao, Yan Guo, Fei Ye, C Michael Stein and Michelle J. Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small RNAs (sRNAs) are important gene regulators and markers of disease. Transfer RNA (tRNA)-derived sRNAs (tDRs), including tRNA fragments (tRFs) and halves (tRHs), are…
Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Malin C Erlandsson^1,2, Minna Turkkila³, Rille Pullerits^2,3,4 and Maria I Bokarewa^2,3, ¹Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ²Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…
Abstract Number: 1501 • 2018 ACR/ARHP Annual Meeting
Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate
Tate Johnson¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Ted R. Mikuls³ and James R. O'Dell⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Multi-Biomarker Disease Activity (MBDA) score was developed to provide an objective measure of rheumatoid arthritis (RA) disease activity. Demonstrating moderate correlations with conventional…
Abstract Number: 2041 • 2018 ACR/ARHP Annual Meeting
Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis
Clémence Gorlier¹, Hafid Ait Oufella², Ludivine Laurans², Alexandra Rousseau³, Sophie Georgin-Lavialle⁴, Harry Sokol⁵, Francis Berenbaum¹, Simon Tabassome⁶, Jacques-Eric Gottenberg⁷ and Jeremie Sellam¹, ¹AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ²Inserm U970, Paris Cardiovascular Research Center, Paris, France, ³AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB, Paris, France, ⁴AP-HP Tenon hospital, Sorbonne Université Paris, Paris, France, ⁵AP-HP Saint-Antoine hospital, Sorbonne Université Paris, France, Paris, France, ⁶AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB), Paris, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France
Background/Purpose: Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is a cell surface receptor expressed mainly on monocytes and neutrophils, known to amplify inflammatory response. We…
Abstract Number: 1355 • 2017 ACR/ARHP Annual Meeting
14-3-3η: Useful for More Than the Diagnosis of Rheumatoid Arthritis?
Lisa Zickuhr¹, Maryam Pourpaki², Martha M. Brooks³ and Amy Joseph⁴, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatology, Advocate Christ Medical Center at Chicago, Oak Lawn, IL, ³Rheumatology, St. Louis VA Medical Center, St. Louis, MO, ⁴Rheumatology, Veterans Administration Central Office, St. Louis, MO
Background/Purpose: Chronic hepatitis C virus (HCV) infection can masquerade as rheumatoid arthritis (RA). Distinguishing between the two is important because treatments differ. 14-3-3η has been…
Abstract Number: 1371 • 2017 ACR/ARHP Annual Meeting
Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage
Jeffrey R. Curtis¹, Darl D. Flake II², Michael Weinblatt³, Nancy A. Shadick⁴, Mikkel Østergaard⁵, Merete Lund Hetland⁶, Cecilie Heegaard Brahe⁶, Yong Gil Hwang⁷, Daniel E. Furst⁸, Vibeke Strand⁹, Carol J. Etzel¹⁰, Dimitrios A. Pappas¹¹, Xingbin Wang¹², Ching Chang Hwang¹³, Eric H. Sasso¹², Alexander Gutin², Elena Hitraya¹² and Jerry S. Lanchbury², ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Myriad Genetics Inc., Salt Lake City, UT, ³Brigham and Women’s Hospital, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Stanford University, Palo Alto, CA, ¹⁰Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ¹¹Columbia University, New York, NY, ¹²Crescendo Bioscience Inc., South San Francisco, CA, ¹³Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The MBDA score, based on 12 serum proteins, is a validated tool for assessing disease activity in RA patients. MBDA biomarkers may be influenced…
Abstract Number: 1377 • 2017 ACR/ARHP Annual Meeting
The Serum Levels of Semaphorin 4D Are Associated with Disease Activity As Well As Radiographic Progression in Patients with Rheumatoid Arthritis
Ji Hyoun Kim¹, You-Jung Ha², Sang Wan Chung³, Eun Ha Kang², Yeong Wook Song^4,5 and Yun Jong Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South), ³Department of Internal Medicine, Department of Internal Medicine, Sarang Hospital, Incheon, Korea, Republic of (South), ⁴Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁵WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)
Background/Purpose: Progranulin (PGRN) and semaphorins (sema) are known to be involved in immune responses as well as bone remodeling process. The aim of this study…
Abstract Number: 1387 • 2017 ACR/ARHP Annual Meeting
In-Depth Temperature of Small and Large Joints Assessed By Microwave Radiometry As an Additional Biomarker in Rheumatoid Arthritis
Katerina Laskari¹, George Pentazos¹, George Konstantonis¹, Ioannis Raftakis², Elias Siores³ and Petros P Sfikakis¹, ¹Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ²Rheumatology Department, Asklepion General Hospital, Athens, Greece, ³Institute of Materials Research and Innovation, University of Bolton, Bolton, United Kingdom
Background/Purpose: Microwave Radiometry (MR) is an easy-to-perform, rapid, non-invasive, objective method, able to measure in-depth tissue temperature. In a proof-of-concept study using joint ultrasound as…
Abstract Number: 1458 • 2017 ACR/ARHP Annual Meeting
Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients
Mark C. Genovese¹, René Galien², Yang Pan³, Annegret Van der Aa⁴, Corinne Jamoul⁴, Pille Harrison⁴, Chantal Tasset⁴, Lovely Goyal³, Wanying Li³ and Jacqueline Tarrant³, ¹Stanford University Medical Center, Palo Alto, CA, ²Galapagos SASU, Romainville, France, ³Gilead Sciences, Foster City, CA, ⁴Galapagos NV, Mechelen, Belgium
Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) was efficacious as both add-on to methotrexate (MTX) and monotherapy in two 24-week phase 2B studies in…
Abstract Number: 1818 • 2017 ACR/ARHP Annual Meeting
Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
S Bandyopadhyay¹, MA Maldonado¹, R Ammar¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Centre, Dallas, TX
Background/Purpose: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models,…
Abstract Number: 1899 • 2017 ACR/ARHP Annual Meeting
Osteopontin and Leptin Are Associated with Erosive Disease in an Inception Cohort of Rheumatoid Arthritis Treated-to-Target with Combination Conventional DMARD Therapy
Mihir D. Wechalekar^1,2,3, Susan Lester⁴, Sunil Nagpal⁵, Suzanne Cole⁶, Jessica Peters⁷, Anuk Das⁸, Pravin Hissaria⁹, Tania Crotti¹⁰, Catherine Hill^1,11,12, Sudha Raghunath¹³, Llew Spargo¹⁴, Jennifer G Walker^13,14,15, Malcolm D. Smith² and Susanna Proudman^1,10, ¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Rheumatology Unit, Repatriation General Hospital, Adelaide, Australia, ⁴Queen Elizabeth Hospital, Adelaide, Australia, ⁵Immunology, Janssen Research & Development, Spring House, PA, ⁶Immunology, Janssen Research and Development, Spring House, PA, ⁷Janssen Research & Development, Spring House, PA, ⁸Janssen R&D, Berwyn, PA, ⁹Immunology, SA Pathology, Adelaide, Australia, ¹⁰University of Adelaide, Adelaide, Australia, ¹¹Medicine, The University of Adelaide, Adelaide, Australia, ¹²The Queen Elizabeth Hospital, Adelaide, Australia, ¹³Repatriation General Hospital, Adelaide, Australia, ¹⁴Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ¹⁵Flinders University of South Australia, Adelaide, Australia
Background/Purpose: We sought to identify biomarkers associated with erosive disease and bone loss in an inception rheumatoid arthritis (RA) cohort receiving treat-to-target combination DMARD therapy…
Abstract Number: 1900 • 2017 ACR/ARHP Annual Meeting
Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Kerri Ford¹, David Chernoff¹, Xingbin Wang¹, Eric H. Sasso¹, Carol J. Etzel^2,3 and Dimitrios A. Pappas^3,4, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: We evaluated the associations between MBDA score and age and between MBDA score and BMI in patients with rheumatoid arthritis (RA). These relationships may…
Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
O Jabado¹, MA Maldonado¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴, William H. Robinson⁵, A Greenfield¹ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴Metroplex Clinical Research Center Dallas, Dallas, TX, ⁵Stanford University, Palo Alto, CA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…
Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting
Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Nathan den Broeder¹, Lieke Tweehuysen¹, Noortje van Herwaarden¹, Thomas Vogl², F.H.J. van den Hoogen¹, Rogier Thurlings³ and Alfons A Den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²University of Muenster, Muenster, Germany, ³Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].